Neuropore Therapies, Inc.
USPTO PatentsView assignee record - 12 granted patents across 4 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Neuropore ranks #23,070 of 49,997 tracked US assignees by granted-patent volume, with 12 patents across 4 technology areas.
- #23,070
- of 49,997 US assignees by volume
- Top 18%
- by Innovation Score (47.9/100)
- 20.0
- avg claims per patent
- +40%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R23070 · US Corporation #23,070 · 12 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-UP · BOOK-FULL
- GRANTS-MICRO 12 grants
- MID-PACK #23,070/49,997
- PHOTO-FINISH Neotech Products
- CPC-NARROW A61P · 4 areas
- INNOV-PAR 47.9/100
- CLAIMS-DENSE 20.0 claims/avg
- TYPE-USCORP US Corporation
- VEL-UP +40% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Neotech Products, LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Neuropore’s 47.9 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Neuropore
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Ecovative Design · near
Ecovative Design · near
48 score
- Neuropore Therapies · this assignee
Neuropore Therapies · this assignee
48 score
- QD Vision · near
QD Vision · near
48 score
- SST Systems · near
SST Systems · near
48 score
- Thin Film ASA · near
Thin Film ASA · near
48 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Neuropore's Innovation Score is 47.9/100 (top 18% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Neuropore?
Each dot is one of Neuropore’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Neuropore’s own 20.0 claims/patent is ABOVE the 11.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Neuropore's grants concentrate
Neuropore Therapies, Inc. is a focused PatentsView assignee: 4 CPC subclasses with 91.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (4 grants) versus a trough of 1 in 2017. By volume, Neuropore sits between Neotech Products, LLC and NewGen Surgical, Inc..
Neuropore's three-year grant acceleration
Neuropore Therapies, Inc. shows 6 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Who files at Neuropore's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Neotech Products
Neotech Products, LLC
12 patents
- Ness Inventions
Ness Inventions, Inc.
12 patents
- Netbio
NetBio, Inc.
12 patents
- Neuraxis
Neuraxis, Inc.
12 patents
- Neurostructures
Neurostructures, Inc.
12 patents
- Nevada Nanotech S…
Nevada Nanotech Systems Inc.
12 patents
- New Wave Endo-sur…
New Wave Endo-Surgical Corp.
12 patents
- Newgen Surgical
NewGen Surgical, Inc.
12 patents
- Neuropore Therapi… ◀
Neuropore Therapies, Inc.
12 patents
What this shows Neuropore holds 12 patents at rank #23,088, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Neuropore
By rank, the assignees closest to #23,088 in granted patent volume.
- Neotech Products, LLC #23,084 · 12 patents
- Ness Inventions, Inc. #23,085 · 12 patents
- NetBio, Inc. #23,086 · 12 patents
- Neuraxis, Inc. #23,087 · 12 patents
- Neurostructures, Inc. #23,089 · 12 patents
- Nevada Nanotech Systems Inc. #23,090 · 12 patents
- New Wave Endo-Surgical Corp. #23,091 · 12 patents
- NewGen Surgical, Inc. #23,092 · 12 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Neuropore's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Assignees with similar portfolio profiles
Two PlainPatent-derived peer sets for Neuropore, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Neuropore ranks #1,740 of 6,058 assignees by patent count in that subclass.
Similar innovation score
Nearest assignees by Innovation Score (48 here).
Neuropore's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
48 Top 18% higher than 82% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 3 | 25.0% |
| 2017 | 1 | 8.3% |
| 2019 | 1 | 8.3% |
| 2021 | 1 | 8.3% |
| 2022 | 4 | 33.3% |
| 2023 | 1 | 8.3% |
| 2024 | 1 | 8.3% |
Which technologies does Neuropore Therapies, Inc. patent most?
Top 4 of 4 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Neuropore Therapies, Inc.'s patent record in context - here's where to go next.
- Neuropore Therapies, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 91.7% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #23,070 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Neuropore Therapies, Inc. against Neotech Products, LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 47.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.